ERIS Lifesciences Ltd (ERIS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1002771, "name": "ERIS Lifescience", "stock_name": "ERIS Lifescience", "full_name": "ERIS Lifesciences Ltd", "name_url": "stocks-analysis/eris-lifescience", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "1,384.00", "chg": -5.45, "chgp": "-0.39%", "dir": -1, "prev_price": "1,389.45", "mcapval": "19,076.00 Cr", "mcap": "Small Cap", "scripcode": 540596, "symbol": "ERIS", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE406M01024", "curr_date": "Aug 07, 03:30 PM", "curr_time": "22:12 PM", "last_traded_at": "Aug 07, 03:30 PM IST", "bse_nse_vol": "42.81 k", "exc_status": "Active", "traded_date": "Aug 07, 2026", "traded_date_str": "2026 08 07", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/eris-lifescience-1002771-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "ERIS Lifesciences Ltd is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-hold-by-marketsmojo-4137724", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/ERISLifescience_mojoScore_4137724.png", "date": "2026-08-05 10:11:29", "description": "ERIS Lifesciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "ERIS Lifesciences Declines 3.30% Amid Valuation Reset and Margin Pressures", "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-declines-330-amid-valuation-reset-and-margin-pressures-4131505", "imagepath": "", "date": "2026-08-01 13:05:35", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>27 Jul:</strong> Stock opens at Rs.1,399.95, marginal gain despite Sensex rally</p>\n <p><strong>29 Jul:</strong> Q1 FY27 results announced with strong sales growth but margin pressure</p>\n <p><strong>31 Jul:</strong> Valuation shifts to fair; stock closes lower at Rs.1,352.75</p>\n <p><strong>31 Jul:</strong> Week closes with a 3.30% decline in stock price versus Sensex +2.39%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,398.90</div></div>\n <div class=\"stat-item\"><div class=\"..." }, { "title": "ERIS Lifesciences Ltd Valuation Shifts to Fair Amidst Sector Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-to-fair-amidst-sector-volatility-4129461", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ERISLifescience_valuationdot_4129461.png", "date": "2026-07-31 08:00:52", "description": "ERIS Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, signalling a more attractive entry point for investors. Despite a recent 3.62% decline in its share price to ₹1,375.60, the pharmaceutical and biotechnology company’s improved price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers and historical averages suggest a recalibration of market expectations amid broader sector dynamics." }, { "title": "Are ERIS Lifesciences Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-eris-lifesciences-ltd-latest-results-good-or-bad-4129071", "imagepath": "", "date": "2026-07-30 19:21:47", "description": "ERIS Lifesciences Ltd's latest financial results for Q1 FY27 indicate a strong topline performance, with net sales reaching ₹873.25 crores, reflecting a year-on-year growth of 12.97%. This growth was driven by robust demand across its chronic therapy portfolio, which includes cardiovascular, anti-diabetic, and gastro-intestinal segments. The company has demonstrated consistent market share gains, achieving a five-year compound annual growth rate (CAGR) of 20.89% in sales.\n\nHowever, the results also reveal challenges, particularly in terms of margin compression. The operating profit margin decreased to 34.09% from 35.86% in the same quarter last year, primarily due to rising employee costs and operational expenses. This contraction in margins highlights the pressures faced by the company in a competitive pharmaceutical landscape.\n\nNet profit for the quarter was reported at ₹142.39 crores, showing a year-on-y..." }, { "title": "ERIS Lifesciences Q1 FY27: Strong Sales Growth Offset by Margin Pressures", "link": "https://www.marketsmojo.com/news/result-analysis/eris-lifesciences-q1-fy27-strong-sales-growth-offset-by-margin-pressures-4127554", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ERISLifescience_quaterlyResult_4127554.png", "date": "2026-07-29 20:18:05", "description": "ERIS Lifesciences Ltd., a speciality pharmaceutical company focused on chronic therapies, reported a consolidated net profit of ₹142.39 crores for Q1 FY27 ended June 2026, marking a sequential decline of 49.44% from ₹281.61 crores in Q4 FY26, though registering a year-on-year growth of 20.68% from ₹117.99 crores in Q1 FY26. The sharp quarter-on-quarter decline was primarily driven by an exceptional tax credit of ₹119.69 crores in the previous quarter, which artificially inflated Q4 FY26 profits. The stock, with a market capitalisation of ₹19,328 crores, closed at ₹1,427.20 on July 29, 2026, up 2.57% from its previous close, though it remains down 20.50% over the past year." }, { "title": "ERIS Lifesciences Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-hold-4120084", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ERISLifescience_mojoScore_4120084.png", "date": "2026-07-25 10:10:41", "description": "ERIS Lifesciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 June 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 25 July 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-technical-momentum-shifts-amid-mixed-market-signals-4117076", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ERISLifescience_technicaldot_4117076.png", "date": "2026-07-23 08:04:21", "description": "ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite this, several technical indicators present a nuanced picture, with weekly and monthly signals diverging, reflecting a complex market sentiment for this pharmaceuticals and biotechnology small-cap stock." }, { "title": "ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-technical-momentum-shifts-amid-mixed-market-signals-4114494", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ERISLifescience_technicaldot_4114494.png", "date": "2026-07-22 08:03:31", "description": "ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more neutral sideways trend. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and volume-based metrics, reflecting a nuanced market sentiment for the pharmaceutical and biotechnology small-cap stock." }, { "title": "ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Indicator Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-4111722", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ERISLifescience_technicaldot_4111722.png", "date": "2026-07-21 08:06:23", "description": "ERIS Lifesciences Ltd has experienced a nuanced shift in its technical momentum, with recent data revealing a transition from a sideways trend to a mildly bearish stance. While some indicators suggest emerging bullishness, others point to caution, reflecting a complex market sentiment for this small-cap pharmaceutical player." } ], "total": 346, "sid": "1002771", "stock_news_url": "https://www.marketsmojo.com/news/eris-lifesciences-1002771" }, "announcements": [ { "caption": "Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Availing Working Capital Term Loan From Axis Bank", "datetime": "06-Aug-2026", "details": "as attached", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript", "datetime": "04-Aug-2026", "details": "As Attached", "source": "BSE" }, { "caption": "Board Meeting Outcome for Outcome Of Board Meeting", "datetime": "29-Jul-2026", "details": "as attached", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "ERIS Lifesciences Ltd has declared <strong>721%</strong> dividend, ex-date: 29 May 26", "dt": "2026-05-29", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

27 Jul: Stock opens at Rs.1,399.95, marginal gain despite Sensex rally

29 Jul: Q1 FY27 results announced with strong sales growth but margin pressure

31 Jul: Valuation shifts to fair; stock closes lower at Rs.1,352.75

31 Jul: Week closes with a 3.30% decline in stock price versus Sensex +2.39%

Week Open

Rs.1,398.90

Read full news article

ERIS Lifesciences Ltd Valuation Shifts to Fair Amidst Sector Volatility

2026-07-31 08:00:52

ERIS Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, signalling a more attractive entry point for investors. Despite a recent 3.62% decline in its share price to ₹1,375.60, the pharmaceutical and biotechnology company’s improved price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers and historical averages suggest a recalibration of market expectations amid broader sector dynamics.

Read full news article

Are ERIS Lifesciences Ltd latest results good or bad?

2026-07-30 19:21:47

ERIS Lifesciences Ltd's latest financial results for Q1 FY27 indicate a strong topline performance, with net sales reaching ₹873.25 crores, reflecting a year-on-year growth of 12.97%. This growth was driven by robust demand across its chronic therapy portfolio, which includes cardiovascular, anti-diabetic, and gastro-intestinal segments. The company has demonstrated consistent market share gains, achieving a five-year compound annual growth rate (CAGR) of 20.89% in sales. However, the results also reveal challenges, particularly in terms of margin compression. The operating profit margin decreased to 34.09% from 35.86% in the same quarter last year, primarily due to rising employee costs and operational expenses. This contraction in margins highlights the pressures faced by the company in a competitive pharmaceutical landscape. Net profit for the quarter was reported at ₹142.39 crores, showing a year-on-y...

Read full news article

ERIS Lifesciences Q1 FY27: Strong Sales Growth Offset by Margin Pressures

2026-07-29 20:18:05

ERIS Lifesciences Ltd., a speciality pharmaceutical company focused on chronic therapies, reported a consolidated net profit of ₹142.39 crores for Q1 FY27 ended June 2026, marking a sequential decline of 49.44% from ₹281.61 crores in Q4 FY26, though registering a year-on-year growth of 20.68% from ₹117.99 crores in Q1 FY26. The sharp quarter-on-quarter decline was primarily driven by an exceptional tax credit of ₹119.69 crores in the previous quarter, which artificially inflated Q4 FY26 profits. The stock, with a market capitalisation of ₹19,328 crores, closed at ₹1,427.20 on July 29, 2026, up 2.57% from its previous close, though it remains down 20.50% over the past year.

Read full news article

ERIS Lifesciences Ltd is Rated Hold

2026-07-25 10:10:41

ERIS Lifesciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 June 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 25 July 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-07-23 08:04:21

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite this, several technical indicators present a nuanced picture, with weekly and monthly signals diverging, reflecting a complex market sentiment for this pharmaceuticals and biotechnology small-cap stock.

Read full news article

ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-07-22 08:03:31

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more neutral sideways trend. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and volume-based metrics, reflecting a nuanced market sentiment for the pharmaceutical and biotechnology small-cap stock.

Read full news article

ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-07-21 08:06:23

ERIS Lifesciences Ltd has experienced a nuanced shift in its technical momentum, with recent data revealing a transition from a sideways trend to a mildly bearish stance. While some indicators suggest emerging bullishness, others point to caution, reflecting a complex market sentiment for this small-cap pharmaceutical player.

Read full news article